Breaking News Instant updates and real-time market news.

HMNY

Helios and Matheson

$7.99

0.26 (3.36%)

, M

Macy's

$24.19

0.04 (0.17%)

08:45
02/13/18
02/13
08:45
02/13/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Helios and Matheson (HMNY) 126.25% +6.83, Macy's (M) 0.48% +0.18, Twitter (TWTR) 0.30% +0.05, Yandex (YNDX) 0.63% +0.04, Itau Unibanco (ITUB) 0.28% +0.03, Wheaton Precious Metals (WPM) 0.28% +0.03, Freeport McMoRan (FCX) 0.26% +0.01, FXI (FXI) 1.80% +0.01, Coca Cola (KO) 0.26% +0.01, and Xunlei (XNET) 21.78% +0.01.

HMNY

Helios and Matheson

$7.99

0.26 (3.36%)

M

Macy's

$24.19

0.04 (0.17%)

TWTR

Twitter

$30.95

-0.56 (-1.78%)

YNDX

Yandex

$36.50

0.61 (1.70%)

ITUB

Itau Unibanco

$15.63

0.16 (1.03%)

WPM

Wheaton Precious Metals

$19.66

0.64 (3.36%)

FCX

Freeport McMoRan

$17.57

(0.00%)

FXI

iShares China Large-Cap ETF

$46.69

0.57 (1.24%)

KO

Coca-Cola

$43.97

0.84 (1.95%)

XNET

Xunlei

$12.61

0.51 (4.21%)

  • 15

    Feb

  • 16

    Feb

  • 17

    Feb

  • 19

    Feb

  • 27

    Feb

  • 28

    Feb

  • 07

    Mar

  • 18

    Mar

  • 22

    Mar

  • 13

    Feb

HMNY Helios and Matheson
$7.99

0.26 (3.36%)

12/05/17
MAXM
12/05/17
NO CHANGE
Target $25
MAXM
Buy
Helios selloff on Cinemark news a buying opportunity, says Maxim
Maxim analyst Brian Kinstlinger views today's selloff in Helios and Matheson Analytics (HMNY) on news of Cinemark's (CNK) monthly subscription offering as a buying opportunity. The stock in afternoon trading is down 20%, or $2.41, to $9.62. Cinemark's offer "provides only modest relief in ticket pricing and essentially locks-in the consumer to see movies only at Cinemark theaters," Kinstlinger tells investors in a research note. He feels MoviePass' offering, at $9.95 per month for unlimited movies to almost any theater, is a "much better value." Separately, the analyst thinks MoviePass, which is 52% owned by Helios and Matheson, has crossed 1M subscribers based on the fact that the annual discounted promotion announced in mid-November is no longer on its website. Kinstlinger keeps a Buy rating on Helios and Matheson with a $25 price target.
12/05/17
LOOP
12/05/17
NO CHANGE
Target $47
LOOP
Buy
Cinemark club a response to MoviePass, but not a loss leader, says Loop Capital
Loop Capital analyst David Miller said Cinemark's (CNK) subscription "Movie Club" is "clearly an answer" to MoviePass, but unlike the latter Cinemark's offering is not intended to be a loss leader and is priced to produce operating income. Miller, who thinks MoviePass' offer is not sustainable but that Cinemark's program should lead to incremental profits, keeps a Buy rating and $47 price target on Cinemark shares. Helios and Matheson Analytics (HMNY) previously has announced that it has agreed to purchase a majority stake in MoviePass.
11/16/17
MAXM
11/16/17
NO CHANGE
Target $25
MAXM
Buy
Maxim sees MoviePass topping 1M subscribers by year end
MoviePass announced a promotion for new or existing subscribers to pay $89.95 upfront for a one year membership, which equates to three months free or $6.95 per month, Maxim analyst Brian Kinstlinger tells investors in a research note. The analyst, who estimates MoviePass' current subscriber base at 750,000-800,000, expects the promotion to drive its subscriber base to more than 1M by the end of 2017. This would be a "major milestone in just four months," Kinstlinger writes. The analyst reiterates a Buy rating on Helios and Matheson Analytics with a $25 price target. The company has a 52% ownership in MoviePass. It is only a matter of time before studios and theaters alike begin negotiating partnerships with movie subscription service, Kinstlinger predicts. Helios and Matheson is up 13c to $12.33 in midday trading.
12/20/17
JPMS
12/20/17
NO CHANGE
JPMS
JPMorgan 'relatively favorable' on movie theaters into 2018
JPMorgan analyst Julia Yue expects improved, although still volatile, box office trends heading into 2018. Cinemark (CNK) and Regal Entertainment (RGC) shares will likely be affected by short-term performance and larger secular fears from any premium-video-on-demand headlines, Yue told investors in a research note detailing her sector outlook for 2018. The analyst has an Overweight rating on Cinemark and Neutral rating on Regal. She's "relatively favorable" on the movie theaters going into next year and projects EBITDA growth, market share gains, and potential further consolidation will drive growth and better share performance. Risks to the companies include MoviePass, of which Helios and Matheson (HMNY) owns a 52% stake, Netflix (NFLX) and higher film rents, Yue contends. The analyst notes MoviePass pays full retail price to the exhibitors for each consumer and sustains the difference between retail price payments to the exhibitors and incoming revenue from its subscribers as a loss. She believes, however, that the service has the potential to change consumers' perceptions of the value of a movie ticket longer term. Over the near term, Yue views the subscription service positively for the exhibitors saying it could drive incremental attendance and concession purchases. Longer term, however, MoviePass could have negative implications for the movie theatres if it were to gain enough subscribers to demand better economics, Yue writes.
M Macy's
$24.19

0.04 (0.17%)

02/05/18
JEFF
02/05/18
NO CHANGE
Target $100
JEFF
Buy
Bon-Ton Stores bankruptcy benefits Kohl's, says Jefferies
Jefferies analyst Randal Konik notes that Bon-Ton Stores filed bankruptcy protection and provided the locations of the about 50 units slated for closure. The analyst now estimates near-term closures from Macy's (M), Sears (SHLD), Kmart, and Bon-Ton (BONT) should add about 18c to Kohl's (KSS) EPS and a 1.5% comp lift. Moreover, Konik believes the materialization of Bon-Ton's closures could be a "cherry on top" to accelerating fundamentals at Kohl's this year. He reiterates a Buy rating and $100 price target on Kohl's shares.
01/02/18
MSCO
01/02/18
NO CHANGE
MSCO
Kohl's, Macy's Q4 same-store sales estimates raised at Morgan Stanley
Morgan Stanley analyst Kimberly Greenberger said that overall retail traffic appeared solid following Christmas, adding that store checks and third party data points suggest better performance at Kohl's (KSS) and Macy's (M) than she originally anticipated. Greenberger raised her Q4 Kohl's comparable sales estimate to down 1% from down 3% and increased her comp sales estimate for Macy's to down 2% from down 2.5%. However, she maintains an Underweight rating on Kohl's shares and an Equal Weight rating on Macy's.
01/05/18
BMOC
01/05/18
NO CHANGE
Target $38
BMOC
Outperform
Macy's price target raised to $38 from $35 at BMO Capital
BMO Capital analyst Wayne Hood raised his price target on Macy's to $38 and kept his Outperform rating after the company's Nov-Dec comps completed the first positive SSS Q4 since 2014. Hood notes "encouraging" improvement in brick-and-mortar comps as well as double digit growth in digital platforms, forecasting further upside from " improving consumer spending setup from tax reform and falling unemployment that could be far reaching". The analyst raises his FY17 EPS forecast to $3.63 from $3.53 and FY18 forecast to $3.18 from $2.63, reflecting a lower effective tax rate of about 25%.
12/18/17
OTRG
12/18/17
UPGRADE
OTRG
Mixed
Macy's upgraded to Mixed from Negative at OTR Global
OTR Global upgraded Macy's to Mixed following checks that indicate sell-through is meeting or exceeding plan driven by strong ecommerce trends.
TWTR Twitter
$30.95

-0.56 (-1.78%)

02/09/18
02/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Sector Perform from Underperform at RBC Capital with analyst Mark Mahaney saying the fourth quarter revenue and EBITDA were materially better than expected, and while MAU's were below consensus, DAU's grew for the first time at a double-digit rate. 2. iRobot (IRBT) upgraded to Outperform from Market Perform at Raymond James with analyst Mark Strouse saying he sees a more balanced risk/reward following the recent pullback in the shares. 3. Regeneron (REGN) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney noting its selloff since last year and believes its valuation has reached a point where the selloff is overdone. 4. Teva (TEVA) upgraded to Sector Perform from Underperform at RBC Capital with analyst Randall Stanicky saying the 11% sell-off in the stock price following the company's guidance update has removed the debate around 2018 EBITDA target and sees limited downside from the current levels. 5. United Technologies (UTX) upgraded to Buy from Hold at Argus with analyst John Eade saying the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/09/18
ARGS
02/09/18
NO CHANGE
Target $40
ARGS
Buy
Twitter price target raised to $40 from $30 at Argus
Argus analyst Jim Kelleher raised his price target on Twitter to $40 and kept his Buy rating after the company's Q4 earning beat. Kelleher cites company accelerating its EPS growth to mid-teens from single digits, expanding margins, and growing international revenue. The analyst sees the stock trading in line with peers on price/sales and EV/EBITDA valuation, recommending shares to "highly risk-tolerant investors".
02/09/18
RHCO
02/09/18
NO CHANGE
Target $29
RHCO
Hold
Twitter price target raised to $29 from $18 at SunTrust
SunTrust analyst Youssef Squali raised his price target on Twitter to $29 after improved monetization seen in the company's Q4 earnings, but says the flat MAU's and high valuation keeps his rating on Hold. Squali points to "growing user engagement and better cost containment leading to record high margins and free cash flow" and believes the momentum is likely sustainable as Twitter management improves the product and the ad platform to attract larger advertisers.
02/12/18
BMOC
02/12/18
NO CHANGE
Target $28
BMOC
Market Perform
Twitter price target raised to $28 from $22 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Twitter (TWTR) to $28 after Q1 results, saying the company has a "clearer strategy" to sustain its revenue momentum thanks to video and AI helping grow mainstream adoption. As top-line pressures fade, writes the analyst in his research note titled "Solid Steps Down Road to Recovery", the stock could become "more interesting", though he is also weary of Facebook (FB) competition still "looming large". Salmon keeps a Market Perform rating on Twitter.
YNDX Yandex
$36.50

0.61 (1.70%)

11/13/17
VTBC
11/13/17
UPGRADE
VTBC
Buy
Yandex upgraded to Buy from Hold at VTB Capital
11/13/17
VTBC
11/13/17
UPGRADE
Target $40
VTBC
Buy
Follow-up: Yandex upgraded to Buy at VTB Capital
As previously reported, VTB Capital upgraded Yandex to Buy from Hold with a $40 price target. Analyst Vladimir Bespalov believes Yandex's ongoing investments into online advertising, taxi, and e-commerce are not fully reflected in valuation and views the recent correction in shares as an attractive entry-point.
01/16/18
DBAB
01/16/18
NO CHANGE
Target $50
DBAB
Buy
Yandex price target raised to $50 from $42 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Yandex to $50 saying he sees "meaningful upside" to the shares over the next three years as the ride share business scales and the company expands Uber Eats in Russia. Yandex Taxi alone could grow to $50 per share by 2023 in a "blue sky scenario," Walmsley tells investors in a research note. Today he values the Yandex pro forma ride share entity with Uber at $12 per share. The analyst reiterates a Buy rating on Yandex.
11/02/17
VTBC
11/02/17
DOWNGRADE
VTBC
Hold
Yandex downgraded to Hold from Buy at VTB Capital
ITUB Itau Unibanco
$15.63

0.16 (1.03%)

12/11/17
DBAB
12/11/17
UPGRADE
Target $16
DBAB
Buy
Itau Unibanco upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Tito Labarta upgraded Itau Unibanco to Buy and raised his price target for the shares to $16 from $11. After spending time in Brazil, the analyst has increased confidence that the economy is recovering. Labarta likes Itau's excess capital, high coverage ratio and "strong" dividend yield.
08/25/17
SBSH
08/25/17
DOWNGRADE
SBSH
Neutral
Itau Unibanco downgraded to Neutral from Buy at Citi
Citi analyst Jorg Friedemann downgraded Itau Unibanco to Neutral from Buy citing the stock's outperformance since May. Macro uncertainties affecting operating trends give him caution after the outperformance, he tells investors.
07/12/17
JPMS
07/12/17
DOWNGRADE
Target $12.5
JPMS
Neutral
Itau Unibanco downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Domingos Falavina downgraded Itau Unibanco to Neutral citing concerns over net investment income growth in the second half of 2017 and 2018. The analyst expects spreads on loans will decrease. He has a $12.50 price target for the shares.
04/11/17
SCOT
04/11/17
UPGRADE
SCOT
Sector Perform
Itau Unibanco upgraded to Sector Perform from Underperform at Scotiabank
WPM Wheaton Precious Metals
$19.66

0.64 (3.36%)

FCX Freeport McMoRan
$17.57

(0.00%)

12/21/17
MSCO
12/21/17
NO CHANGE
MSCO
Equal Weight
Cleveland-Cliffs a key beneficiary of corporate AMT repeal, says Morgan Stanley
Morgan Stanley analyst Piyush Sood noted that Steel Dynamics (STLD) and Nucor (NUE) have been the "preferred tax reform plays" in the steel sector, but he believes that Cleveland-Cliffs (CLF), as well as Warrior Met Coal (HCC) and Freeport McMoran (FCX), should benefit from the corporate alternative minimum tax repeal, as they all carry substantial AMT credits on their balance sheets. He keeps Equal Weight ratings on Cleveland, Warrior and Freeport.
01/17/18
CLKS
01/17/18
UPGRADE
CLKS
Buy
Freeport McMoRan upgraded to Buy from Neutral at Clarksons Platou
Clarksons Platou upgraded Freeport McMoRan to Buy citing an increased copper price deck and a better medium to long-term outlook for Grasberg.
01/26/18
SBSH
01/26/18
NO CHANGE
Target $20
SBSH
Neutral
Freeport believes Grasberg risk largely mitigated, says Citi
Citi analyst Alexander Hacking says Freeport McMoRan (FCX) management, in a conference call, confirmed its preference that Rio Tinto (RIO) sell its 40% Grasberg stake to the government. The tone seemed to suggest that many key issues remain to be resolved, thus a deal is not imminent, Hacking tells investors in a research note. Further, the analyst notes that Freeport management believes project risk is largely mitigated based on development to date. This is very positive, Hacking writes. Hacking adds that Freeport is aiming to resume dividend payments over the coming quarters. He raised his price target for the shares to $20 from $16 and keeps a Neutral rating Freeport. A successful resolution in Indonesia and $3.18/lb long-term copper price are fully priced into the shares, Hacking contends.
01/21/18
CIBC
01/21/18
DOWNGRADE
CIBC
Neutral
Freeport McMoRan downgraded to Neutral from Outperformer at CIBC
CIBC downgraded Freeport McMoRan to Neutral citing recent shares strength.
FXI iShares China Large-Cap ETF
$46.69

0.57 (1.24%)

KO Coca-Cola
$43.97

0.84 (1.95%)

01/30/18
BERN
01/30/18
NO CHANGE
Target $124
BERN
Market Perform
Dr Pepper Snapple price target raised to $124 from $92 at Bernstein
Bernstein analyst Ali Dibadj raised his price target for Dr Pepper Snapple to $124 from $92 after the company and Keurig Green Mountain announced a definitive merger agreement to create public company Keurig Dr Pepper. While the analyst views this merger as good for Dr Pepper Snapple shareholders, there are unanswered questions about the prospects as a combined entity, with revenue synergies remaining unclear, synergy targets appearing stretched, and the Coca-Cola (KO)/PepsiCo (PEP) distribution partnership remaining a risk. Dibadj reiterates a Market Perform rating on Dr Pepper Snapple's shares.
01/29/18
RHCO
01/29/18
INITIATION
Target $125
RHCO
Hold
PepsiCo initiated with a Hold at SunTrust
As reported earlier, SunTrust analyst William Chappell initiated PepsiCo (PEP) with a Hold rating and a price target of $125. Chappell contends that after 5 years of price and promotion with Coca-Cola (KO), the companies' next phase will likely see "price increases or at least less promotional activity" on some beverage items. The analyst also notes that the investor concerns about the snacking category are overblown, pointing some recovery in Q4, while the positive FX, emerging markets, and tax reform dynamics create more tailwinds.
01/18/18
SUSQ
01/18/18
NO CHANGE
Target $54
SUSQ
Neutral
Monster Beverage current U.S. growth not sustainable, says Susquehanna
Susquehanna analyst Pablo Zuanic said he expects Monster Beverage (MNST) to provide good guidance commentary, but he is concerned about margin pressures and lower overseas growth. He does not think the U.S. growth rate is sustainable and also does not believe regulatory risk is priced in, nor is continued margin pressure. Zuanic also said he does not see a bid from Coca-Cola (KO). Zuanic reiterated his Negative rating and lowered his price target to $54 from $56 on Monster Beverage shares.
01/12/18
EVER
01/12/18
UPGRADE
EVER
Outperform
Coca-Cola upgraded to Outperform from In Line at Evercore ISI
XNET Xunlei
$12.61

0.51 (4.21%)

TODAY'S FREE FLY STORIES

NTRA

Natera

$14.07

-0.55 (-3.76%)

05:07
06/22/18
06/22
05:07
06/22/18
05:07
Hot Stocks
Natera announces new kidney transplant rejection biomarker »

Natera announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$438.06

-8.23 (-1.84%)

05:00
06/22/18
06/22
05:00
06/22/18
05:00
Recommendations
Abiomed analyst commentary  »

Abiomed price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECL

Ecolab

$141.52

-2.14 (-1.49%)

04:57
06/22/18
06/22
04:57
06/22/18
04:57
Downgrade
Ecolab rating change  »

Ecolab downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
06/22/18
06/22
04:55
06/22/18
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

June PMI Composite Flash…

QGEN

Qiagen

$36.20

-0.23 (-0.63%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Qiagen participates in a conference call with William Blair »

CFO Sachers participates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

04:55
06/22/18
06/22
04:55
06/22/18
04:55
General news
PMI Composite Flash Manufacturing â€' Level to be reported at 09:45 »

June PMI Composite Flash…

AOBC

American Outdoor Brands

$12.80

-0.42 (-3.18%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
American Outdoor Brands management to meet with Wedbush »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

NGVT

Ingevity

$82.89

-0.12 (-0.14%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Ingevity management to meet with Loop Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SBUX

Starbucks

$50.62

-1.6 (-3.06%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Starbucks management to meet with Wedbush »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 10

    Jul

AMGN

Amgen

$186.00

-0.51 (-0.27%)

, ARRY

Array BioPharma

$19.56

-0.43 (-2.15%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO World Congress on…

AMGN

Amgen

$186.00

-0.51 (-0.27%)

ARRY

Array BioPharma

$19.56

-0.43 (-2.15%)

BAYRY

Bayer

$0.00

(0.00%)

HALO

Halozyme

$18.59

-0.88 (-4.52%)

INCY

Incyte

$72.47

-0.97 (-1.32%)

LLY

Eli Lilly

$86.07

-0.17 (-0.20%)

MRK

Merck

$61.17

-0.125 (-0.20%)

SHPG

Shire

$162.43

1.81 (1.13%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$39.02

-0.38 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 23

    Jun

  • 28

    Jun

  • 30

    Jun

  • 30

    Jun

  • 10

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Dec

  • 28

    Jan

  • 22

    Mar

TAC

TransAlta

$4.95

(0.00%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
TransAlta management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

NUVA

NuVasive

$55.48

-1.18 (-2.08%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
NuVasive has a conference call hosted by JPMorgan »

JPMorgan Analyst Marcus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

HUBG

Hub Group

$53.05

-0.8 (-1.49%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Hub Group management to meet with Loop Capital »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

PVAC

Penn Virginia

$79.38

-1.7 (-2.10%)

, ALOG

Analogic

$83.98

0.025 (0.03%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Hot Stocks
Penn Virginia to replace Analogic in S&P 600 at open on June 22 »

Altaris Capital Partners…

PVAC

Penn Virginia

$79.38

-1.7 (-2.10%)

ALOG

Analogic

$83.98

0.025 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$48.68

-1.035 (-2.08%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Fluor management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Macquarie to hold a summit »

Emerging Industries…

INST

Instructure

$45.00

-1.675 (-3.59%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Instructure management to meet with Needham »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

RLH

Red Lion Hotels

$11.70

-0.15 (-1.27%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Red Lion Hotels management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Stephens food/agribusiness analyst to hold an analyst/industry conference call »

Food & Agribusiness…

04:55
06/22/18
06/22
04:55
06/22/18
04:55
General news
Breaking General news story  »

Week of 6/22 Baker-Hughes…

NUVA

NuVasive

$55.48

-1.18 (-2.08%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
NuVasive management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

IRTC

iRhythm

$79.00

-1.67 (-2.07%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
iRhythm management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

EURN

Euronav NV

$9.80

0.1 (1.03%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Euronav NV management to meet with Seaport Global »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

PRMW

Primo Water

$17.78

0.02 (0.11%)

04:55
06/22/18
06/22
04:55
06/22/18
04:55
Conference/Events
Primo Water management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SWN

Southwestern Energy

$5.27

-0.105 (-1.95%)

04:54
06/22/18
06/22
04:54
06/22/18
04:54
Recommendations
Southwestern Energy analyst commentary  »

Southwestern Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.